182results about "Ester active ingredients" patented technology

The present application relates to a pharmaceutical composition comprising an NRF2 agonist and borneol, both of which synergize in a specific molar ratio range, enhance the overall anti-inflammatory and antioxidant biological activity of the drug, improve the oral bioavailability and target tissue distribution of the drug, inhibit the off-target side effects of the NRF2 agonist, and significantly improve the effectiveness and safety of the drug.

The present invention discloses compositions and methods comprising enriched bisdemethoxycurcumin (BDMC) present at 20% by weight or greater for use in inhibiting receptor for advanced glycation end products (RAGE) expression in a subject with a chronic inflammatory condition. The composition further comprises beta-amyrin palmitate (BAP). The present invention also discloses the use of the composition in managing a chronic inflammatory condition in a subject.

In certain embodiments, Formula I: 【Chemical 1】 Compounds of JPEG2025520456000046.jpg5339 or pharmaceutically acceptable salts or solvates thereof, compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and their use in the treatment of certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation) etc. are provided herein.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and / or pterostilbene - Pomegranate extract and / or - Sulforaphane or a source of sulforaphane; and - Vitamin D.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The present invention relates to a carbamoylphenylalaninol compound and a method of using the same for enhancing one or more cognitive functions in subjects having cognitive impairments associated with obstructive sleep apnea and excessive daytime sleepiness, and for treating one or more cognitive impairments in such subjects.

The present invention provides a method and apparatus (e.g., a device, a system, etc.) that can be used to deliver one or more agents (e.g., drugs, biologics, compounds, compositions, etc., including cells, etc.) to target tissue in or near the outer membrane through nutrient vessels. [Solution] These methods and apparatus can be used, in particular, to deliver relatively large amounts of drugs to target tissue in or near the outer membrane through nutrient vessels.

A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and / or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.

This invention relates to the field of pharmaceutical injection technology, specifically to a neostigmine methylsulfate injection and its preparation method. The preparation method of the neostigmine methylsulfate injection of this invention includes the following steps: S1 pretreatment of water for injection, S2 preparation, S3 filtration, S4 filling and sealing, and S5 sterilization. This invention features a simple process, high yield, and low cost. It effectively reduces the generation of impurity I in the neostigmine methylsulfate injection, improves the storage stability of the product, reduces potential medication safety hazards caused by impurities, and ensures drug quality and medication safety.

Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically 10 acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

The present invention relates to compositions comprising at least one lipid-lowering drug or a derivative thereof for the treatment of skin diseases or disorders. In various aspects of the invention, the composition further comprises at least one lipid or a derivative thereof.

A composition comprising silicone pressure sensitive adhesive and an amine functional drug, wherein the amine functional drug is dispersed in the silicone pressure sensitive adhesive.

Disclosed are azotomycin prodrugs their use in treating diseases, disorders, or conditions associated with excess and / or aberrant glutamine utilization, including cancer.

Disclosed herein are antisense oligonucleotides, such as gapmer antisense oligonucleotides with modified backbone chemistry (e.g., with one or more spacers).Such gapmer antisense oligonucleotides with modified backbone chemistry can be useful for treating various diseases, such as neurological diseases.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Prodrugs of itaconic acid and 1- and 4-methyl itaconic acid and their use for treating a disease, disorder, or condition associated with inflammation are disclosed.

The application discloses a liver and heart double-targeted mitochondrial fatty acid oxidation activator, and relates to the technical field of activators.The activator comprises a complex structure composed of the following components in cooperation: a biaxial isomerized fatty acyl cluster core composed of two types of conformational mirror image long-chain fatty acyl units, wherein: the cis-carboxylic acid tail end reversible folding type fatty acyl unit is combined with carnitine palmitoyltransferase-1 in liver cells to promote the transport of fatty acids to the mitochondrial matrix.The application realizes the phase separation of liver and heart mitochondria beta-oxidation, the synchronization of electron flow and the dynamic protection of ROS by constructing a biaxial isomerized fatty acyl cluster core and combining a quantum self-regulating coenzyme bridge chain and a self-shielding peroxidation regulation group, and maintains the cross-organ energy chain homeostasis.The activator significantly improves the energy transmission efficiency and system stability, prevents membrane potential resonance and metabolic imbalance, realizes the transformation of liver and heart energy from synchronous energy consumption to self-regulating homeostasis, and has important physiological and clinical application value.

Disclosed is a pharmaceutical composition, comprising an NRF2 agonist and borneol. The NRF2 agonist and the borneol act synergistically within a specific molar ratio range to enhance the overall anti-inflammatory and anti-oxidation biological activities of the drug, improve the oral bioavailability and target tissue distribution of the drug, and inhibit the off-target side effects of the NRF2 agonist, resulting in significant improvement in the drug efficacy and safety.

The application discloses an amino benzene sulfonamide derivative and application thereof. The structural general formula of the amino benzene sulfonamide derivative is shown in the following formula. The amino benzene sulfonamide derivative has good pepsin inhibitory activity, can effectively block the adhesion and reactivation of pepsin in the pharyngeal mucosa, and has super high selectivity in the internal proteinase family compared with other non-specific protease inhibitors, thereby significantly reducing the off-target risk of normal physiological proteases in the human body. In addition, the compound is particularly suitable for local spray administration in the throat, can maintain a high concentration in the lesion site, and overcomes the defect of traditional oral antacid drugs in the insufficient effect on non-acid reflux, thereby providing a new solution for the treatment of throat reflux diseases.

The application discloses application of tegaserod maleate in preparation of an antibacterial drug synergist, and proves that the tegaserod maleate can produce a synergistic antibacterial effect with a plurality of commonly used antibacterial drugs (including tylosin, tetracycline, enrofloxacin, ampicillin and the like), can significantly enhance the antibacterial activity of the antibacterial drugs on gram-negative bacteria, and reduce the drug resistance of bacteria to the antibacterial drugs; the antibacterial composition composed of the tegaserod maleate and the antibacterial drugs can be used for preparing a drug for treating escherichia coli infection, and the synergistic antibacterial mechanism is mainly to destroy the inner and outer membrane permeability of bacteria, regulate the proton motive force of bacteria, inhibit the activity of bacterial efflux pumps, interfere with the energy metabolism homeostasis of bacteria and induce the bacteria to produce oxidative stress. The application provides a new technical strategy for the treatment of clinical escherichia coli infection, and has important clinical application value and industrialization potential.

A composition that includes one or more plant-based ingredients, natural extracts, polyphenolic compounds, yeast, vitamins, minerals, and fats to provide a composition generally intended to be administered orally to support and promote a healthy heart, cardiovascular system, and immune system. The composition may comprise, in one exemplary embodiment, a combination of psyllium, tomato extract, fenugreek extract, resveratrol, red yeast rice extract, and medium chain triglyceride (MCT) oil, vitamins C, D3, E, and A, zinc, selenium (as selenomethionine), and Myrciaria dubai or organic camu camu fruit powder in various amounts.

This invention provides a system for in-situ cardiac NO generation based on bioorthogonal reactions and its application, belonging to the pharmaceutical field. The system of this invention improves the bioavailability of NO in the heart, thereby significantly improving myocardial ischemia-reperfusion injury. Specifically, microneedles are pre-implanted into the heart, and then a delivery system (prepared by modifying L-arginine with trans-cyclooctene to form an L-arginine prodrug, and then preparing a nano-delivery system by electrostatic adsorption of L-Arg-TCO) is injected into the body via intravenous injection. Only when the nano-delivery system circulates to the heart, and the TCO undergoes a bioorthogonal reaction with (4-(6-methyl-1,2,4,5-tetraazinecyclo-3-yl)phenyl)methylamine in the microneedles, can the L-arginine prodrug be activated, thereby achieving cardiac-targeted delivery of L-arginine, leading to the enrichment, activation, and conversion of L-arginine into NO in the heart.

Aspects of the present disclosure relate to compositions and methods for treating a subject having a neurodegenerative disorder, disease or condition. Particular aspects relate to treatment with a therapeutically effective amount of a composition comprising a vector encoding an Aβ peptide variant. Further aspects relate to a method of inhibiting aggregation of endogenous Aβ peptide in vivo by contacting at least one endogenous Aβ peptide in vivo with a therapeutically effective amount of an Aβ peptide variant expressed from a vector encoding the Aβ peptide variant, said vector being present in a composition.

This invention belongs to the field of natural product chemistry, and relates to characteristic vibsane-type diterpenoids with a seven-membered ring skeleton from *Viburnum awabuki*, or their salts, as well as their preparation methods and applications. Specifically, this invention relates to 15 vibsane-type diterpenoids with a seven-membered ring skeleton extracted and isolated from the dried leaves of *Viburnum awabuki*, a plant in the Viburnaceae family. The vibsane-type diterpenoids were isolated by silica gel column chromatography, HP20 macroporous resin column chromatography, ODS column chromatography, and HPLC. The antitumor activity of these compounds was investigated by testing their inhibitory effects on three tumor cell lines: HepG2, A549, and MCF-7.

The present invention provides a non-aqueous preparation that comprises 5-ALA, a derivative thereof, or a salt of these, and that has excellent stability of the 5-ALA, the derivative, or the salt of these. A non-aqueous preparation according to the present invention comprises: a compound represented by the following general formula (I) or a salt thereof; a sugar or a sugar alcohol; and at least one substance selected from the group consisting of fatty acids, fatty acid esters, aliphatic hydrocarbons, and aliphatic alcohols with a melting point of 30-100°C. [In general formula (I), R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group.]